Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.75 |
| ▸ | S1PR3 | Q99500 | 16/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15926064 | 0.97 | S1PR1 (0.71) | S1PR1S1PR3MEN1ALDH1A1KMT2A | |
| SCHEMBL12382068 | 0.93 | S1PR1 (0.75) | S1PR1S1PR3MEN1ALDH1A1KMT2A | |
| SCHEMBL12315629 | 0.86 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL12382069 | 0.84 | S1PR1 (0.77) | S1PR1S1PR3MEN1ALDH1A1KMT2A | |
| SCHEMBL17295333 | 0.80 | S1PR1 (0.60) | S1PR1S1PR3MEN1ALDH1A1KMT2A | |
| SCHEMBL17295332 | 0.80 | S1PR1 (0.60) | S1PR1S1PR3MEN1ALDH1A1KMT2A | |
| SCHEMBL12315653 | 0.80 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL13576510 | 0.79 | MEN1 (0.78) | S1PR1S1PR3MEN1ALDH1A1KMT2A | |
| SCHEMBL12315641 | 0.79 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL19096610 | 0.79 | S1PR1 (0.67) | S1PR1S1PR3MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912340-B2 | Process for the preparation of 2-imino-thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-12-16 | — | — | US | disclosed |
| US-8912340-B2 | Process for the preparation of 2-imino-thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-12-16 | — | — | US | disclosed |
| US-20120302758-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | VANDA PHARMACEUTICALS INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302758-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | VANDA PHARMACEUTICALS INC. | 2012-11-29 | — | — | US | disclosed |
| US-8263780-B2 | Process for the preparation of 2-imino-thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8263780-B2 | Process for the preparation of 2-imino-thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-09-11 | — | — | US | disclosed |
| US-20110201821-A2 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATES | VANDA PHARMACEUTICALS INC. | 2011-08-18 | — | — | US | disclosed |
| US-20110201821-A2 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATES | VANDA PHARMACEUTICALS INC. | 2011-08-18 | — | — | US | disclosed |
| US-20100317867-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-16 | — | — | US | disclosed |
| US-20100317867-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-16 | — | — | US | disclosed |
| WO-2008062376-A2 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317867-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | IL4, IL15, IL2 | S1PR1 3394/4885S1PR3 3399/4885MEN1 690/4885 |
| US-20110201821-A2 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATES | IL4, IL2, IL15 | S1PR1 3355/4885S1PR3 3539/4885MEN1 415/4885 |
| US-20120302758-A1 | NEW PROCESS FOR THE PREPARATION OF 2-IMINO-THIAZOLIDIN-4-ONE DERIVATIVES | IL4, IL15, IL2 | S1PR1 3394/4885S1PR3 3399/4885MEN1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.